Search - tctmd.com

Displaying 1 - 20 of 173

Sort: Relevancy | Date

News Daily News

JACC Debuts Data Digest on CV Health in the United States

Caitlin E. Cox

January 12, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Better LDL Control After STEMI Means Less Neoatherosclerosis

Yael L. Maxwell

December 23, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

L.A. McKeown

March 21, 2025

News Daily News

Cannabis Use Again Tied to Increased CVD Risk in Young People

L.A. McKeown

March 19, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

High Levels of Metals, Particularly Cadmium, Linked to Subclinical CVD

Michael O'Riordan

September 23, 2024

Advertisement

JACC Debuts Data Digest on CV Health in the United States

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Year in Review: Top Prevention Stories of 2025

Better LDL Control After STEMI Means Less Neoatherosclerosis

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Risk Calculators Miss Many Patients Who Present With First MI

September 2025 Dispatch for the CV Team

CVD Still the Leading Cause of Death and Disease Globally

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

March 2025 Dispatch for the CV Team

Cannabis Use Again Tied to Increased CVD Risk in Young People

ACC/AHA Release New Comprehensive ACS Guidelines

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

High Levels of Metals, Particularly Cadmium, Linked to Subclinical CVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content